Tumor Suppressive Maspin-Sensitized Prostate Cancer to Drug Treatment Through Negative Regulating Androgen Receptor Expression

Tumor Suppressive Maspin-Sensitized Prostate Cancer to Drug Treatment Through Negative Regulating Androgen Receptor Expression

Overactivation of androgen receptor (AR)-mediated signal has been extensively implicated in prostate cancer (CaP) development, progression, and recurrence, which makes it an attractive therapeutic target. Meanwhile, as an endogenous inhibitor of histone deacetylase 1 (HDAC 1), tumor-suppressive mamm...

Full description

Bibliographic Details
Main Authors:	Sijie Tang, Xueqi Lian, Jiajia Jiang, Huiying Cheng, Jiaqian Guo, Can Huang, Hong Meng, Xiaohua Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-10-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	maspin androgen receptor HDAC inhibitor chemotherapy castration-resistant prostate cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2020.573820/full

Similar Items

Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells
by: Neal Corey L, et al.
Published: (2012-08-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

Role of maspin in cancer
by: Rossana Berardi, et al.
Published: (2013-12-01)

Clinical relevance of androgen receptor alterations in prostate cancer
by: Emma Jernberg, et al.
Published: (2017-10-01)

Clamp ablation of the testes compared to bilateral orchiectomy as androgen deprivation therapy for advanced prostate cancer
by: AD Zarrabi, et al.
Published: (2011-06-01)

Androgen receptor signaling in prostate cancer development and progression
by: Peter E Lonergan, et al.
Published: (2011-01-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)

Regulation of androgen receptor variants in prostate cancer
by: Yezi Zhu, et al.
Published: (2020-07-01)

Posttranslational Modification of the Androgen Receptor in Prostate Cancer
by: Haojie Huang, et al.
Published: (2013-07-01)

Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
by: Mauro Scaravilli, et al.
Published: (2021-02-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)

Maspin impairs the function of endothelial cells: an implying pathway of preeclampsia
by: Ying Zhang, et al.
Published: (2017-09-01)

Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells
by: Kouji Izumi, et al.
Published: (2019-03-01)

Maspin and MCM2 immunoprofiling in salivary gland carcinomas
by: Helmy Iman M, et al.
Published: (2011-09-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
by: Osamu Ogawa, et al.
Published: (2013-07-01)

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: Jiaxin Wang, et al.
Published: (2020-11-01)

Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
by: Marzieh Ehsani, et al.
Published: (2021-03-01)

Maspin as a Tumour Suppressor in Salivary Gland Tumour
by: Bassel Tarakji, et al.
Published: (2014-12-01)

Maspin expression in epithelial skin tumours: An immunohistochemical study
by: Asmaa Gaber Abdou, et al.
Published: (2011-01-01)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

The evolution of prostate cancer therapy: targeting the androgen receptor (AR)
by: Jeanny B. Aragon-Ching
Published: (2014-10-01)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
by: Yuki Kita, et al.
Published: (2018-09-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Jo-Lynn Tan, et al.
Published: (2017-12-01)

Hexane Insoluble Fraction from Purple Rice Extract Retards Carcinogenesis and Castration-Resistant Cancer Growth of Prostate Through Suppression of Androgen Receptor Mediated Cell Proliferation and Metabolism
by: Ranchana Yeewa, et al.
Published: (2020-02-01)

The maspin expression in canine mammary tumors: an immunohistochemical and molecular study A expressão do maspin nos tumores mamários caninos: um estudo imuno-histoquímico e molecular
by: Debora A.P.C. Zuccari, et al.
Published: (2009-02-01)

Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: two case reports
by: Mohan Hingorani, et al.
Published: (2014-12-01)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
by: Namrata Khurana, et al.
Published: (2020-01-01)

Role of Androgen Receptor in Prostate Cancer: A Review
by: Kazutoshi Fujita, et al.
Published: (2019-09-01)

The AhR Ligand, TCDD, Regulates Androgen Receptor Activity Differently in Androgen-Sensitive versus Castration-Resistant Human Prostate Cancer Cells
by: Maryam Ghotbaddini, et al.
Published: (2015-07-01)

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
by: Paul S. Rennie, et al.
Published: (2013-06-01)

Analysis of Maspin Expression in Invasive Ductal Carcinoma of the Breast on Stages IIA and IIIB
by: Arif Satria Hardika, et al.
Published: (2018-04-01)

Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients
by: Mark A. Underwood, et al.
Published: (2013-08-01)

Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer
by: Xiaochuan Shan, et al.
Published: (2015-09-01)

Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer
by: Xiaochuan Shan, et al.
Published: (2018-04-01)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
by: Qin Feng, et al.
Published: (2019-09-01)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
by: Takashi Nagai, et al.
Published: (2018-03-01)

Expression of maspin in benign and malignant salivary gland tumors: An immunohistochemical study
by: V Reshma, et al.
Published: (2014-01-01)

Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models
by: Jinny Sun, et al.
Published: (2021-02-01)

Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
by: Daniel J. Crona, et al.
Published: (2017-06-01)